Stay updated on Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial page
- Check3 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check10 days agoChange DetectedThe ClinicalTrials.gov footer now identifies the site revision as v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check17 days agoChange DetectedThe footer’s site revision number changed from v3.7.0 to v3.7.1 while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe page now shows a 403 Forbidden error indicating restricted access to the study record. Additionally, sponsor-related content and study documents associated with Merck were removed from the page.SummaryDifference22%

- Check59 days agoChange DetectedThe page now includes a 2015 NIH grant/contract annotation and updates the release version from v3.6.5 to v3.6.6.SummaryDifference0.1%

- Check80 days agoChange DetectedA new revision tag 'Revision: v3.6.5' has been added, and the 'Plain Language Summary' section along with the previous 'Revision: v3.6.4' has been removed, indicating an update to the page's content and presentation.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial page.